Utah Medical Products, Inc. Reports Corrected Results of Tender Offer

The completed repurchase totaled $24,580,500, with administration fees, SEC filing fees and a further excise tax adding costs.

Rhea-AI Summary

Utah Medical Products (Nasdaq:UTMD) purchased 327,740 common shares in its tender offer, which expired October 27, 2026. The purchase totaled $24,580,500 at $75.00 per share, versus an offer for up to 650,000 shares. Remaining shares outstanding were 2,849,041, including 1,775 employee option shares exercised in October. The effective tender cost was $75.35 per share; a further 1% excise tax will apply to share repurchases.

1 point · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 4 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point327,740 shares repurchased at $75.00 each returned $24,580,500 to tendering shareholders. 11% of market cap

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.$107,720 administration fees will be paid to the depositary and information agent.
• Minor point$6,732 SEC filing fees add to tender offer costs.
• Minor point. Forward-looking: it has not happened yet and may not happen.1% federal excise tax will additionally apply to share repurchases.
• Minor point1,775 employee option shares exercised in October added to shares outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, UT / ACCESS Newswire / October 29, 2026 / On September 24, Utah Medical Products, Inc. (Nasdaq:UTMD) offered to purchase up to 650,000 shares of its common stock at $75.00 per share. The issuer Tender Offer expired Tuesday October 27.

In short, 327,740 shares were purchased for $24,580,500. Remaining UTMD shares outstanding at this date are 2,849,041 including 1,775 employee option shares exercised in October.

In addition, $107,720 administration fees will be paid to the depositary and information agent, and $6,732 in filing fees to the SEC. The effective cost of the tender offer was 75.35/ share. Another 1% excise tax will be levied by the federal government on share repurchases.

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.

Contact:

Brian Koopman
(801) 566-1200

SOURCE: Utah Medical Products, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Utah Medical Products purchase in its tender offer?

Utah Medical Products purchased 327,740 shares at $75.00 per share, totaling $24,580,500. The offer had sought up to 650,000 shares and expired October 27, 2026.